Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Armistice Capital and Steven Boyd report beneficial ownership of 4,897,417 shares of Travere Therapeutics common stock (5.27%) via a joint Schedule 13G filing. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and Mr. Boyd may be deemed to beneficially own them as managing member. The Master Fund disclaims beneficial ownership arising solely from its inability to vote or dispose of the shares under its Investment Management Agreement with Armistice Capital.
Travere Therapeutics completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. The notes are senior unsecured, pay 0.50% interest semi-annually, and mature on May 15, 2032, unless earlier repurchased, redeemed or converted.
The initial conversion rate is 15.4078 shares per $1,000 principal (conversion price about $64.90 per share), with a maximum of 11,729,182 shares issuable based on an initial maximum conversion rate of 22.3413. Travere estimates net proceeds of about $508.5 million.
The company intends to use roughly $350.9 million of the proceeds to repurchase about $221.4 million principal of its outstanding 2.25% senior convertible notes due 2029 and will use the remaining proceeds for general corporate purposes, including commercialization, R&D, capital expenditures, working capital and administrative expenses.
Travere Therapeutics is offering $475,000,000 aggregate principal amount of 0.50% convertible senior notes due 2032, with an underwriter option for an additional $50,000,000. The notes pay 0.50% interest, mature on May 15, 2032, and have an initial conversion rate of 15.4078 shares per $1,000 (approximate conversion price $64.90 per share). Conversions are permitted only upon specified stock-price, note-trading-price, corporate-event or redemption conditions and, if converted, will be settled in cash, shares or a combination at the company’s election. Travere expects to use a portion of net proceeds to repurchase part of its 2.25% convertible senior notes due 2029 and the remainder for general corporate purposes. The offering is not intended to be listed and settlement is expected on or about May 11, 2026.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold the resulting shares in a pre-planned transaction. On May 5, he exercised options for 4,500 shares of common stock at $18.27 per share and sold 4,500 shares at $46.65 per share in an open-market sale. The sale was made under a written Rule 10b5-1(c) trading plan adopted on November 17, 2025 and involved fully vested, exercisable options. After these transactions, Baynes directly owns 37,500 shares of Travere Therapeutics common stock, with no remaining position from the exercised options.
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares of common stock at $16.33 per share, then sold 8,000 shares at $45.00 per share in an open‑market transaction. The sale was made under a pre‑arranged Rule 10b5‑1(c) trading plan. Following these transactions, Meckler directly owns 87,500 shares of Travere Therapeutics common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported a mix of equity award activity and a small share sale. On May 4, 2026, 4,250 performance-based restricted stock units converted into common stock after a cumulative FILSPARI net revenue performance criterion was met, and he received a new grant of 8,500 performance-based units. The filing notes that an additional 25% of these units is scheduled to vest on January 31, 2027, contingent on continued service. On May 6, 2026, he sold 2,763 shares of common stock at $43.95 per share under a pre-arranged Rule 10b5-1 trading plan that also covered tax obligations from the vesting. Following the transactions, he directly holds 115,474 common shares.
Travere Therapeutics, Inc. Chief Legal Officer and General Counsel Elizabeth E. Reed reported a mix of option exercises, PSU activity and share sales. On May 4, 2026 she exercised employee stock options and performance-based restricted stock units covering a total of 24,250 shares of common stock, including 20,000 options at a $17.96 exercise price.
That same day, she sold 20,000 shares at $45.00 per share, and on May 5 and 6, 2026 she sold additional blocks of 2,174 shares at $46.65 and 2,076 shares at $43.95. Footnotes state that certain sales were made under a Rule 10b5‑1 trading plan and that some shares were sold to cover tax withholding obligations related to vested performance-based RSUs, rather than as discretionary trades. After these transactions, she directly held 105,211 shares of Travere common stock and performance-based restricted stock units covering 8,500 shares at target.
Travere Therapeutics Chief Medical Officer Jula Inrig reported a combination of equity award activity and stock sales. On May 4, 2026, she exercised 20,000 employee stock options with a $22.40 exercise price and sold 20,000 shares of common stock at $45.00 per share, alongside the vesting and conversion of 4,250 performance-based restricted stock units (PSUs) into common stock.
On May 5 and 6, 2026, she sold additional blocks of 2,174 and 311 shares at $46.65 and $43.95 per share. Footnotes state that certain sales, including tax “sell to cover” transactions, were conducted under a pre-arranged Rule 10b5-1 trading plan rather than as fully discretionary trades. Following these transactions, Inrig directly holds 113,238 shares of common stock, plus 34,500 stock options and 8,500 PSUs subject to future vesting conditions.
Travere Therapeutics’ chief commercial officer Peter Heerma reported a mix of equity award vesting and a required tax-related sale. On May 4, 2026, 4,250 performance-based restricted stock units (PSUs) vested, converting into 4,250 shares of common stock after Travere confirmed a FILSPARI cumulative net revenue performance milestone tied to results for the quarter ended March 31, 2026.
Those PSUs are part of an 8,500-unit grant awarded on January 31, 2024, with an additional 25% scheduled to vest on January 31, 2027, contingent on continued service. The filing notes that up to 50% additional shares could vest later if certain milestones are achieved on an accelerated timeline. On May 5, 2026, Heerma sold 2,174 shares at $46.65 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement chosen by the company, described as a non-discretionary sale. After these transactions, he directly holds 140,684 shares of Travere common stock.